Project Oncology®

Host: Steve Jackson, PharmD Guest: Paolo F. Caimi, MD Guest: Narendranath Epperla, MD, MS As both CAR T-cell therapy and bispecific antibodies become increasingly integrated into the treatment of R/R LBCL, it’s important to consider the evidence in the context of individual patient factors and disease characteristics. In this conversation with Dr. Steve Jackson, Dr. Paolo Caimi and Dr. Naren Epperla examine the evidence guiding these approaches and discuss how they think about sequencing decisions in these patients. Dr. Caimi is the Associate BMT Director for Cellular Therapy at the Cleveland Clinic Cancer Institute and an Associate Professor in the Department of Medicine at the Case Western Reserve University School of Medicine. Dr. Epperla is an Associate Professor of Medicine and Associate Chief of Clinical Research in the Division of Hematology at the University of Utah Huntsman Cancer Institute. This is a non-certified educational series produced and controlled by ReachMD.

Guest: John Cho, MD, PhD, FRCPC Could lower doses of radiation help optimize immune response in mesothelioma? Dr. John Cho joins us to explain how tailoring radiation to a tumor’s inflammatory and immunogenic characteristics could help modulate antitumor immunity while reducing the potential for fibrosis and treatment-related toxicity. Dr. Cho is a radiation oncologist at the Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto, and he spoke about this topic at the 2026 World Conference on Lung Cancer.

Guest: Angel Qin, MD The treatment landscape for ALK+ metastatic non-small cell lung cancer (mNSCLC) is continuing to evolve, with durable outcomes from frontline ALK inhibition and emerging therapies offering new possibilities across disease settings. Join Dr. Angel Qin, Clinical Associate Professor of Internal Medicine at the University of Michigan Medical School, as she examines the evidence on current and emerging treatment options for this population.

Guest: Angel Qin, MD Even with increasingly effective targeted therapies for ALK+ metastatic non-small cell lung cancer (mNSCLC), unanswered questions remain, especially when a patient's disease progresses or treatment becomes difficult to tolerate. In this program, Dr. Angel Qin looks beyond current care strategies to consider where the field is headed, from overcoming resistance to investigating entirely different ways of extending disease control. Dr. Qin is a Clinical Associate Professor of Internal Medicine at the University of Michigan Medical School.

Guest: Angel Qin, MD Checkpoint inhibitors have shown limited efficacy in ALK+ metastatic non-small cell lung cancer (mNSCLC), but could a different immunologic strategy complement targeted therapy? Dr. Angel Qin discusses the rationale for ALK vaccines and explains how harnessing an ALK-specific immune response may help extend the durability of ALK TKI therapy. She's a Clinical Associate Professor of Internal Medicine at the University of Michigan Medical School.